lansoprazole has been researched along with Enterocolitis, Pseudomembranous in 6 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Enterocolitis, Pseudomembranous: An acute inflammation of the INTESTINAL MUCOSA that is characterized by the presence of pseudomembranes or plaques in the SMALL INTESTINE (pseudomembranous enteritis) and the LARGE INTESTINE (pseudomembranous colitis). It is commonly associated with antibiotic therapy and CLOSTRIDIUM DIFFICILE colonization.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients enrolled in a long-term trial of lansoprazole for Zollinger-Ellison syndrome and other acid hypersecretory states had interval histories taken every six months regarding hospitalizations or other intercurrent medical conditions." | 7.74 | Absence of gastrointestinal infections in a cohort of patients with Zollinger-Ellison syndrome and other acid hypersecretors receiving long-term acid suppression with lansoprazole. ( Hirschowitz, BI; Martin, T; Mohnen, J; Phadnis, M; Wilcox, CM; Worthington, J, 2008) |
| "Patients enrolled in a long-term trial of lansoprazole for Zollinger-Ellison syndrome and other acid hypersecretory states had interval histories taken every six months regarding hospitalizations or other intercurrent medical conditions." | 3.74 | Absence of gastrointestinal infections in a cohort of patients with Zollinger-Ellison syndrome and other acid hypersecretors receiving long-term acid suppression with lansoprazole. ( Hirschowitz, BI; Martin, T; Mohnen, J; Phadnis, M; Wilcox, CM; Worthington, J, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wilcox, CM | 1 |
| Martin, T | 1 |
| Phadnis, M | 1 |
| Mohnen, J | 1 |
| Worthington, J | 1 |
| Hirschowitz, BI | 1 |
| Kaur, S | 2 |
| Vaishnavi, C | 2 |
| Prasad, KK | 2 |
| Ray, P | 2 |
| Kochhar, R | 2 |
| Rai, R | 1 |
| Rai, S | 1 |
| Kubo, N | 1 |
| Kochi, S | 1 |
| Ariyama, I | 1 |
| Murata, M | 1 |
| Furusyo, N | 1 |
| Hayashi, J | 1 |
| Lau, CF | 1 |
| Hui, PK | 1 |
| Fung, TT | 1 |
| Tung, SY | 1 |
| Wong, AM | 1 |
| Loo, CK | 1 |
| Lam, KM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Long-Term Study of the Efficacy and Safety of Lansoprazole in the Treatment of Zollinger-Ellison and Other Acid Hypersecretors[NCT00204373] | Phase 4 | 72 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
number of participants with control of gastric acid production (NCT00204373)
Timeframe: up to 240 months from study enrollment
| Intervention | participants (Number) |
|---|---|
| Single Group | 72 |
The median survival from the time of diagnosis (NCT00204373)
Timeframe: survival or up to 240 months
| Intervention | years (Median) |
|---|---|
| Single Group | 6.6 |
6 other studies available for lansoprazole and Enterocolitis, Pseudomembranous
| Article | Year |
|---|---|
Absence of gastrointestinal infections in a cohort of patients with Zollinger-Ellison syndrome and other acid hypersecretors receiving long-term acid suppression with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti | 2008 |
Effect of Lactobacillus acidophilus & epidermal growth factor on experimentally induced Clostridium difficile infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ampicillin; Animals; Cecum; Clostridioides difficile; Colon | 2011 |
Pseudomembranous colitis requiring surgical intervention following triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Clarithromycin; Drug Therapy, Combination; Enterocol | 2002 |
[Pseudomembranous colitis after Helicobacter pylori eradication therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Ag | 2006 |
Comparative role of antibiotic and proton pump inhibitor in experimental Clostridium difficile infection in mice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ampicillin; Animals; Anti-Bacterial Agents; Bacterial Toxin | 2007 |
Pseudomembranous colitis without diarrhoea following Helicobacter pylori eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents | 2001 |